Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now

Stuttgart - Delayed Quote EUR

Takeda Pharmaceutical Co Ltd (TKD.SG)

Compare

26.28

-0.22

(-0.83%)

As of 8:17:48 AM GMT+1. Market Open.

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

OSAKA, Japan & CAMBRIDGE, Mass., January 30, 2025--Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Takeda’s U.S. Business Unit, as the successor to Christophe Weber, Takeda’s president, chief executive officer (CEO) and representative director, when Mr. Weber retires from the company in June 2026. Mrs. Kim will be proposed as a candidate for election to the Board at Takeda’s Annual General Shareho

Business Wire 22 days ago

TAK

TKPHF
0.00%
Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

OSAKA, Japan, January 30, 2025--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the third quarter of fiscal year 2024 (nine months ended December 31, 2024) showing continued advancement of its Growth & Launch Products, which delivered double-digit growth of 14.6% at CER. The company has upgraded its full year outlook for growth, reflecting strong year-to-date product performance and OPEX efficiencies, as well as revised foreign exchange assumptions.

Business Wire 22 days ago

TAK

TKPHF
0.00%
Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age

Takeda Canada Inc. (Takeda) is pleased to announce that Héma-Québec has added HyQvia®– (normal immunoglobulin [human] 10% and recombinant human hyaluronidase solution for subcutaneous infusion) as a replacement therapy for primary humoral immunodeficiency (PI) or secondary humoral immunodeficiency (SI) – to its list of plasma products distributed in Quebec.1 The treatment will now be reimbursed for adult and pediatric patients two years of age and older starting January 30, 2025,

CNW Group 23 days ago

TAK

TKPHF
0.00%
Stocks to watch this week: ASML, Intel, LVMH, Shell and Glencore

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 28 days ago

AON

WHTPF

LMT
Takeda Recognized as a Top Employer in Canada for Third Consecutive Year

Today, Takeda Canada Inc. ("Takeda") announced that, for the third consecutive year, it has received Top Employer® certification for 2025. Takeda is one of just 17 companies that received global recognition, and it also was certified as a Top Employer in 24 countries.

CNW Group last month

TAK

TKPHF
0.00%
Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the global development and commercialization license agreement with Takeda (TSE:4502/NYSE:TAK)

GlobeNewswire last month

TAK

TKPHF
0.00%
KROS
Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)

Takeda Canada Inc. ("Takeda") is pleased to announce that Health Canada has provided market authorization for FRUZAQLA™ (fruquintinib capsules), indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with or are not considered candidates for available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF agent, an anti-EGFR agent (if RAS wild-type), and either trifluridine-ti

CNW Group last month

TAK

TKPHF
0.00%
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

OSAKA, Japan & CAMBRIDGE, Mass., December 27, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that the Japanese Ministry of Health, Labour and Welfare has approved the use of HYQVIA® [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (PID) or secondary imm

Business Wire last month

TAK

TKPHF
0.00%
Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative

Takeda Canada Inc. (Takeda) is proud to sponsor the Inaugural MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellows Initiative. This program aims to standardize training, organize networks, and implement Entrustable Professional Activities (EPAs) for advanced IBD fellows in Canada.

CNW Group 2 months ago

TAK

TKPHF
0.00%
Takeda Announces Subsidiary Liquidation and Merger Completion

Takeda Pharmaceutical Company ( (TAK) ) has shared an update. Takeda Pharmaceutical Company has submitted an extraordinary report detailing its decision to dissolve its specified subsidiary, Shire Pharmaceuticals International Unlimited Company, through liquidation. This move results in a significant change in the voting rights structure, marking the completion of a merger process where Takeda now holds no voting rights in the subsidiary. The liquidation process will follow local regulations, al

TipRanks 2 months ago

TAK

TKPHF
0.00%
HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

— US$10 million milestone payment to HUTCHMED follows first national reimbursement in Europe — — Follows June 2024 European approval of FRUZAQLA® (fruquintinib), the first novel oral targeted therapy in the EU for metastatic colorectal cancer regardless of biomarker status in over a decade — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Dec. 12, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$10 million milestone

GlobeNewswire 2 months ago

TAK

TKPHF
0.00%
HCM
Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

OSAKA, Japan & CAMBRIDGE, Mass., December 12, 2024--Takeda Spotlights High-Value, Late-Stage Pipeline of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Business Wire 2 months ago

TAK

TKPHF
0.00%
Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

OSAKA, Japan & CAMBRIDGE, Mass., December 03, 2024--Takeda (TSE:4502/NYSE:TAK) today announced that it has entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (Nasdaq: KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.

Business Wire 2 months ago

TAK

TKPHF
0.00%
Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

Keros Therapeutics to receive upfront payment of $200 million and is eligible to receive development, approval and commercial milestone payments with the potential to exceed $1.1 billion and tiered royalties on net sales LEXINGTON, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that a

GlobeNewswire 2 months ago

TAK

TKPHF
0.00%
KROS
Takeda’s Strong FY2024 H1 Boosts Full-Year Outlook

Takeda Pharmaceutical Company (TAK) has released an update. Takeda Pharmaceutical Company has raised its full-year management guidance for FY2024 following a robust first-half performance, driven by the successful launch of several new products and a return to double-digit growth for its established drug ENTYVIO. The company’s Growth & Launch Products segment saw an 18.7% increase at constant exchange rates, comprising nearly half of Takeda’s total revenue. With a focus on expanding its innovati

TipRanks 2 months ago

TAK

TKPHF
0.00%
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to HUTCHMED from Takeda — — Fruquintinib already launched in several regions including the United States, Europe and China — HONG KONG, SHANGHAI & FLORHAM PARK, N.J., Nov. 21, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a milestone payment following the pricing approval and launch of FRUZA

GlobeNewswire 2 months ago

HCM

HMDCF

TAK
New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD

Takeda Canada Inc. ("Takeda") announces new data highlighting the impact Inflammatory Bowel Disease (IBD) has on Canadians. The data reveals insights into how the disease affects daily life, the challenges to timely access to care and treatment, and the unmet need to prioritize mental health support for those living with IBD.

CNW Group 3 months ago

TAK

TKPHF
0.00%
HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

— US$20 million payment based on sales of FRUZAQLA® in metastatic colorectal cancer —HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will receive a US$20 million milestone payment from its partner Takeda (TSE:4502/NYSE:TAK), triggered by reaching over US$200 million in sales of FRUZAQLA® (fruquintinib) for metastatic colorectal cancer (“CRC”). CRC is the second most commo

GlobeNewswire 3 months ago

HCM

HMDCF

TAK
Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

OSAKA, Japan, October 31, 2024--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first half of fiscal year 2024 (six months ended September 30, 2024), with continued momentum in its Growth & Launch Products driving growth. The company has upgraded its full year forecasts and Management Guidance to reflect stronger than anticipated first-half performance (including milder than anticipated generic erosion of VYVANSE® in the U.S.) and revised foreign exchange assumptions.

Business Wire 3 months ago

TAK

TKPHF
0.00%
Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

CAMBRIDGE, Mass. & BOSTON, October 24, 2024--Takeda (TOKYO:4502/NYSE:TAK) and Boston Medical Center (BMC) today announced a new collaboration focused on identifying innovative solutions that can reduce hard-to-abate greenhouse gas (GHG) emissions in the health care sector. The collaboration between Takeda and BMC aims to reduce the GHG emissions caused by disposal of regulated medical waste, such as pharmaceutical packaging and single-use plastics, which are among the most difficult environmenta

Business Wire 3 months ago

TAK

TKPHF
0.00%

Performance Overview

Return	TKD.SG	Nikkei 225
YTD	+4.41%	-2.80%
1-Year	-86.42%	+1.35%
3-Year	-99.42%	+44.09%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Takeda Pharmaceutical Co Ltd (TKD.SG)

Julie Kim Will Succeed Christophe Weber as CEO of Takeda in June 2026

Takeda Delivers Strong Third-Quarter FY2024 Results; Raises Full Year Outlook, Forecasting Revenue and Core Operating Profit Margin Growth

Héma-Québec to Reimburse HyQvia® for the Treatment of Immunodeficiencies in Adult and Pediatric Patients Over 2 Years of Age

Stocks to watch this week: ASML, Intel, LVMH, Shell and Glencore

Takeda Recognized as a Top Employer in Canada for Third Consecutive Year

Keros Therapeutics Announces Effectiveness of Global License Agreement with Takeda to Advance Elritercept

Takeda's FRUZAQLA™ (fruquintinib) Receives Health Canada Market Authorization for Metastatic Colorectal Cancer (mCRC)

Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

Takeda Sponsors MILESTONE Canada Advanced Inflammatory Bowel Disease (IBD) Fellowship Initiative

Takeda Announces Subsidiary Liquidation and Merger Completion

HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)

Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas

Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics

Keros Therapeutics Announces Global License Agreement with Takeda to Advance Elritercept

Takeda’s Strong FY2024 H1 Boosts Full-Year Outlook

HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan

New Survey Data Highlights the Importance of Prioritizing Mental Health for Canadians Living with IBD

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda

Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook

Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem

Performance Overview